Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab with Radiation in Metastatic Pancreatic Cancer
NCT04409002Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2020
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab, sponsored by Massachusetts General Hospital. Started Jul 2020; status: completed.
02
Drugs
niraparibdostarlimab
Beyond the preview
Go deeper on NCT04409002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409002.